– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC. | June 3, 2023
An oral presentation titled "Phase 1/2 Study of DF1001, an Immune Modulating TriNKET® Targeting HER2, in Patients with Advanced Solid Tumors: Phase 1 DF1001 Monotherapy Dose Escalation Results"
Treatment with BDC-1001 at the recommended Phase 2 dose resulted in 29% objective response rate in evaluable patients with HER2-positive tumors, in both monotherapy and in combination with. | May 25, 2023
— Complete data from Phase 1A clinical trial of SL-172154 as monotherapy in platinum-resistant ovarian cancer to be presented at the 2023 American Society of Clinical Oncology annual meeting. | May 9, 2023